Safety of implantable contraceptives for women: Data from observational studies

Contraception

Volumn 65, Issue 1, 2002, Pages 85-96

  Curtis, Kathryn M ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

Contraception; Etonogestrel; Implants; Levonorgestrel; Safety

Indexed keywords

CONTRACEPTIVE AGENT; ELCOMETRINE; ETONOGESTREL; LEVONORGESTREL; NOMEGESTROL ACETATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; BONE DENSITY; BONE MINERAL; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTRACEPTION; DEATH; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG IMPLANT; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG USE; FEMALE; GALLBLADDER DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INTRAUTERINE CONTRACEPTIVE DEVICE; MENTAL DISEASE; OBSERVATION; OUTCOMES RESEARCH; PELVIC INFLAMMATORY DISEASE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; THROMBOCYTOPENIA;

BONE DENSITY; COHORT STUDIES; CONTRACEPTIVE AGENTS, FEMALE; CONTROLLED CLINICAL TRIALS; DELIRIUM, DEMENTIA, AMNESTIC, COGNITIVE DISORDERS; DIABETES MELLITUS; DRUG IMPLANTS; FEMALE; GALLBLADDER DISEASES; HEMATOLOGIC DISEASES; HIV INFECTIONS; HUMANS; HYPERTENSION; MORTALITY; NEOPLASMS; PELVIC INFLAMMATORY DISEASE;

EID: 0036178216     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(01)00291-8     Document Type: Review

References (64)

1. Norplant consensus statement and background review
2. Facts about an implantable contraceptive: Memorandum from a WHO meeting
3. An integrated analysis of nonmenstrual adverse events with Implanon
4. Three-year experience with Norplant subdermal contraception
5. Post-marketing surveillance of Norplant contraceptive implants: II. Non-reproductive health
6. Safety and efficacy of levonorgestrel implants, IUD, and sterilization
7. A 5-year evaluation of Norplant contraceptive implants in China
8. Post-marketing surveillance of Norplant contraceptive implants: I. Contraceptive efficacy and reproductive health
9. Cervical carcinogenesis and contraception
10. Cervical cytology associated with levonorgestrel contraception
11. A 2-year comparative study of endometrial histology and cervical cytology of contraceptive implant users in Birmingham, UK
12. Serious adverse events in Norplant users reported to the Food and Drug Administration's MedWatch Spontaneous Reporting System
13. Serious adverse events in Norplant users reported to the Food and Drug Administration's MedWatch Spontaneous Reporting System
14. Norplant implants and cardiovascular disease
15. Introduction of Norplant implants in four counties of rural China: A two-year evaluation
16. A multicentre efficacy and safety study of the single contraceptive implant Implanon
17. A 10-year follow-up study of contraceptive Norplant implants
18. Study of Norplant implants in Shanghai: Three-year experience
19. Contraception with Norplant implants and Norplant-2 implants (two covered rods). Results from a comparative clinical study in Sweden
20. A five-year clinical evaluation of Norplant contraceptive subdermal implants in Bangladeshi acceptors
21. Use of Norplant in Pakistan: Two years experience
22. Five-year experience with Norplant implants in Assiut, Egypt
23. A cohort study of Norplant implant: Side-effects and acceptance
24. Multicenter clinical trial on the efficacy and acceptability of a single contraceptive implant of nomegestrol acetate, Uniplant
25. Five-year evaluation of safety, efficacy and acceptability of Norplant implants in Nepal
26. A five-year clinical evaluation of Norplant subdermal implants in Sri Lanka
27. Blood pressure changes and hormonal contraceptives
28. The effect of low-dose oral contraceptives and Norplant on blood pressure and body weight of Nigerian women
29. A prospective study of adolescents who choose among levonorgestrel implant (Norplant), medroxyprogesterone acetate (Depo-Provera), or the combined oral contraceptive pill as contraception
30. A five-year evaluation of Norplant II implants in China
31. Bone density in women receiving Norplant implants for contraception
32. Bone mineral density during long-term treatment with Norplant implants and depot medroxyprogesterone acetate. A cross-sectional study of Thai women
33. Steroid hormone contraception and bone mineral density: A cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health
34. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives
35. Norplant implants and progesterone vaginal rings do not affect maternal bone turnover and density during lactation and after weaning
36. Bone mineral density during long-term use of the progestogen contraceptive implant Implanon compared to a non-hormonal method of contraception
37. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women
38. Effects of levonorgestrel-releasing subdermal contraceptive implants on bone density and bone metabolism
39. Metabolic effects of implantable steroid contraceptives for women
40. Changes in carbohydrate metabolism during 30 months on Norplant
41. Glucose metabolism among Norplant users in northern Nigeria
42. The effect of continuous subdermal levonorgestrel (Norplant) on carbohydrate metabolism
43. Carbohydrate metabolism before and after Norplant removal
44. Insulin sensitivity is unaltered by the use of the Norplant subdermal implant contraceptive
45. The effect of Norplant on glucose metabolism under hyperglycemic hyperinsulinemic conditions
46. Effect of Norplant implants on liver, lipid, and carbohydrate metabolism
47. Short-term and long-term effects of Norplant-2 on plasma lipoproteins and glucose tolerance
48. Effect of Norplant-2 rods on liver, lipid, and carbohydrate metabolism
49. The effects of nomegestrol acetate subdermal implant (Uniplant) on carbohydrate metabolism, serum lipoproteins, and on hepatic function in women
50. Unaltered lipoprotein and carbohydrate metabolism during treatment with contraceptive subdermal implants containing ST-1435
51. Subdermal levonorgestrel implants. Three years' experience in Cairo, Egypt
52. Nonmenstrual adverse events during use of implantable contraceptives for women: Data from clinical trials
53. A pilot efficacy study with a single-rod contraceptive implant (Implanon) in 200 Indonesian women treated for < or = 4 years
54. Effects of contraceptives on hemoglobin and ferritin
55. Possible association between the Norplant contraceptive system and thrombotic thrombocytopenic purpura
56. Implanon. A review of clinical studies
57. Effects of two progestin-only contraceptives, Depo-Provera and Norplant-II, on the vaginal epithelium of rhesus monkeys
58. The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy
59. Use of Norplant implants in asymptomatic HIV-1 infected women
60. Toxicology of polymers for implant contraceptives for women